CN Patent

CN116942671B — ALK inhibitor 2在制备治疗食管鳞癌的药物中的应用

Assigned to Air Force Medical University · Expires 2024-02-27 · 2y expired

What this patent protects

本发明属于医药领域，具体涉及ALK inhibitor 2在制备治疗食管鳞癌的药物中的应用。本发明的究结果表明，ALK inhibitor 2能够高效抑制RSK4酶的表达，且能够高效的抑制食管鳞癌细胞的增殖、侵袭和迁移，与Afatinib联用，能够显著抑制食管鳞癌埃克替尼耐药株的增殖，该结果为食管鳞癌患者的治疗和预后提供了一种有效的技术手段。

USPTO Abstract

本发明属于医药领域，具体涉及ALK inhibitor 2在制备治疗食管鳞癌的药物中的应用。本发明的究结果表明，ALK inhibitor 2能够高效抑制RSK4酶的表达，且能够高效的抑制食管鳞癌细胞的增殖、侵袭和迁移，与Afatinib联用，能够显著抑制食管鳞癌埃克替尼耐药株的增殖，该结果为食管鳞癌患者的治疗和预后提供了一种有效的技术手段。

Drugs covered by this patent

Patent Metadata

Patent number
CN116942671B
Jurisdiction
CN
Classification
—
Expires
2024-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Air Force Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.